{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:28:30Z","timestamp":1767144510768,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.adengl.2021.11.020","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"record-id":"37954"},{"DOI":"10.1016\/j.adengl.2021.11.020","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000}}],"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.adengl.2021.11.020","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T22:55:03Z","timestamp":1637880903000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WITHDRAWN: Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19"],"prefix":"10.1016","author":[{"given":"D.","family":"Morgado-Carrasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ibaceta-Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Piquero-Casals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adengl.2021.11.020_bib0005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2017.01.012","article-title":"Updated recommendations on the use of hydroxychloroquine in dermatologic practice","volume":"76","author":"Fernandez","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0010","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1111\/ajd.13168","article-title":"Hydroxychloroquine in dermatology: new perspectives on an old drug","volume":"61","author":"Chew","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/idoj.IDOJ_280_20","article-title":"Hydroxychloroquine in dermatology and beyond: recent update","volume":"11","author":"Sardana","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.adengl.2021.11.020_bib0020","article-title":"To dispense or not to dispense: lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic","author":"Cox","year":"2020","journal-title":"Dev World Bioeth"},{"key":"10.1016\/j.adengl.2021.11.020_bib0025","article-title":"Competing health risks associated with the COVID-19 pandemic and response: a scoping review","author":"Baral","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.adengl.2021.11.020_bib0030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.23296","article-title":"Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-Deficient patients","volume":"70","author":"Mohammad","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.adengl.2021.11.020_bib0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/jrheum.200395","article-title":"Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic","volume":"47","author":"Peschken","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.07.027","article-title":"An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review","volume":"82","author":"Shipman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1346-8138.14802","article-title":"Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients","volume":"46","author":"Ototake","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamadermatol.2018.5215","article-title":"Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers","volume":"155","author":"Pinard","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijwd.2017.05.001","article-title":"The systemic management of cutaneous dermatomyositis: results of a stepwise strategy","volume":"3","author":"Anyanwu","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.12.032","article-title":"Myeloid dendritic cells are major producers of interferon-\u03b2 in dermatomyositis and may contribute to hydroxychloroquine refractoriness","volume":"141","author":"Chen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0070","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaad.2021.02.034","article-title":"Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris","volume":"85","author":"Akabane","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0075","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaad.2019.01.040","article-title":"Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo Clinic, 1996-2013","volume":"80","author":"Kumar","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","article-title":"Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases","volume":"17","author":"Lakhanpal","year":"1988","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.adengl.2021.11.020_bib0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2018.09.007","article-title":"Treatment of urticarial vasculitis: a systematic review","volume":"143","author":"Kolkhir","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0095","first-page":"e14903","article-title":"Successful systemic treatment outcomes of lichen planus: a single-center retrospective review","author":"Hunt","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.adengl.2021.11.020_bib0100","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/j.1440-0960.2010.00695.x","article-title":"Childhood actinic lichen planus: successful treatment with antimalarials","volume":"53","author":"Ram\u00edrez","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0105","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1111\/ajd.12948","article-title":"Hydroxychloroquine sulphate therapy of erosive oral lichen planus","volume":"60","author":"Yeshurun","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0190-9622(93)70082-5","article-title":"Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial","volume":"28","author":"Eisen","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000439588","article-title":"Antimalarial drugs for the treatment of oral erosive lichen planus","volume":"232","author":"Rivas-Tolosa","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.adengl.2021.11.020_bib0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bjd.19870","article-title":"The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina","volume":"185","author":"Vermeer","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12463","article-title":"The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review","volume":"30","author":"Nic Dhonncha","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.adengl.2021.11.020_bib0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2009.08.054","article-title":"Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system","volume":"62","author":"Chiang","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/ijpvm.IJPVM_156_17","article-title":"Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial","volume":"8","author":"Naeini","year":"2017","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.adengl.2021.11.020_bib0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2019.03.079","article-title":"Medical therapy for frontal fibrosing alopecia: a review and clinical approach","volume":"81","author":"Ho","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0145","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2133.2010.09965.x","article-title":"Frontal fibrosing alopecia: a clinical review of 36 patients","volume":"163","author":"Samrao","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0150","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2013.12.003","article-title":"Frontal fibrosing alopecia: a multicenter review of 355 patients","volume":"70","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/pde.13451","article-title":"Alopecia areata treated with hydroxychloroquine: a retrospective study of nine pediatric cases","volume":"35","author":"Yun","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.23822\/EurAnnACI.1764-1489.11","article-title":"Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study","volume":"49","author":"Boonpiyathad","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2016.11.044","article-title":"Antimalarial therapy for granuloma annulare: Results of a retrospective analysis","volume":"76","author":"Grewal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000086452","article-title":"Treatment of generalized granuloma annulare with hydroxychloroquine","volume":"211","author":"Cannistraci","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.adengl.2021.11.020_bib0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/archderm.144.1.118","article-title":"Successful treatment of necrobiosis lipoidica with antimalarial agents","volume":"144","author":"Durupt","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0180","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-4632.2010.04149.x","article-title":"Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine","volume":"49","author":"Kavala","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0190-9622(90)70246-E","article-title":"Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas","volume":"23","author":"Jones","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0190","first-page":"351","article-title":"Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate","volume":"81","author":"Modi","year":"2008","journal-title":"Cutis"},{"key":"10.1016\/j.adengl.2021.11.020_bib0195","first-page":"312","article-title":"Ulcerative sarcoidosis: a prototypical presentation and review","volume":"100","author":"Powell","year":"2017","journal-title":"Cutis"},{"key":"10.1016\/j.adengl.2021.11.020_bib0200","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","article-title":"Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda","volume":"10","author":"Singal","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0205","first-page":"286","article-title":"A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients","volume":"1","author":"Marchesi","year":"1984","journal-title":"Photodermatology"},{"key":"10.1016\/j.adengl.2021.11.020_bib0210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0378-6323.38401","article-title":"Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study","volume":"74","author":"Pareek","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2133.1987.tb05852.x","article-title":"Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring","volume":"116","author":"Murphy","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0220","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0190-9622(08)81962-7","article-title":"Antimalarials for children","volume":"30","author":"Maga\u00f1a-Garc\u00eda","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0225","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2020.05.050","article-title":"Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, double-dummy, pilot study","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0230","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2133.1996.tb07635.x","article-title":"Hydroxychloroquine and chronic erythema nodosum","volume":"134","author":"Jarrett","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ad.2020.09.004","article-title":"Familiar dermatologic drugs as therapies for COVID-19","volume":"112","author":"Ortega-Pe\u00f1a","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.adengl.2021.11.020_bib0240","doi-asserted-by":"crossref","first-page":"e13829","DOI":"10.1111\/dth.13829","article-title":"Treatment of COVID 19-Repurposing drugs commonly used in dermatology","volume":"33","author":"Stojkovic-Filipovic","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.adengl.2021.11.020_bib0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijmmb.2021.03.002","article-title":"The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 \u2014 a systematic review and meta-analysis","volume":"39","author":"Choudhuri","year":"2021","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.adengl.2021.11.020_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2020-218164","article-title":"Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics","volume":"80","author":"Mendel","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.adengl.2021.11.020_bib0255","doi-asserted-by":"crossref","first-page":"e13524","DOI":"10.1111\/dth.13524","article-title":"The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic","volume":"33","author":"Shah","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.adengl.2021.11.020_bib0260","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4269\/ajtmh.20-0290","article-title":"Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in Africa: caution for inappropriate off-label use in healthcare settings","volume":"102","author":"Abena","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.adengl.2021.11.020_bib0265","first-page":"CD013587","article-title":"Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19","volume":"2","author":"Singh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.adengl.2021.11.020_bib0270","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa2021801","article-title":"A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19","volume":"384","author":"Mitj\u00e0","year":"2021","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1016\/j.adengl.2021.11.020","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"record-id":"37954"},{"DOI":"10.1016\/j.adengl.2021.11.020","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000}}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1578219021003243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1578219021003243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:55:44Z","timestamp":1761623744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1578219021003243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":54,"alternative-id":["S1578219021003243"],"URL":"https:\/\/doi.org\/10.1016\/j.adengl.2021.11.020","relation":{},"ISSN":["1578-2190"],"issn-type":[{"value":"1578-2190","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adengl.2021.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}